Profile cover photo
Profile photo
Next Biotech
10 followers
10 followers
About
Posts

Post has attachment
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing.

Post has attachment
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing.

Post has attachment
Creso Pharma (ASX:CPH) is in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc.

Post has attachment
Creso Pharma (ASX:CPH) is in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc.

Post has attachment
CPH is looking to build a sustainable foothold in the Australian medicinal cannabis market and extend its reach well beyond domestic shores as well.

Post has attachment
CPH is looking to build a sustainable foothold in the Australian medicinal cannabis market and extend its reach well beyond domestic shores as well.

Post has attachment
Immuron Limited (ASX: IMC) is working in the realm of oral immunotherapies, targeting inflammatory-mediated and infectious diseases and is uniquely positioned to address large unmet needs.

Post has attachment
Immuron Limited (ASX: IMC) is certainly taking the fastest route it can to a NASDAQ listing and expect to be listed within months.

Post has attachment
Creso Pharma (ASX: CPH) has become the first ASX listed company to import medicinal cannabis products into Australia under new government legislation, as it looks to capitalize on growing interest and demand.

Post has attachment
Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation.
Wait while more posts are being loaded